Analyst firms · Robert W. Baird · CLLS
Robert W. Baird CLLS price target and rating history
Cellectis S.A. (CLLS) · Health Care
Robert W. Baird rates Cellectis S.A. (CLLS) Outperform with a $10 price target, as of its latest action on May 18, 2022. It has published 3 rating actions on CLLS since October 2021, including 1 upgrade and 2 downgrades.
- Current rating
- Outperform
- Price target
- $10
- Median target, all firms
- Too few
- Actions on CLLS
- 3
Robert W. Baird price target on CLLS
Every Robert W. Baird rating on CLLS
- May 18, 2022
- Oct 8, 2021
- Oct 8, 2021
How other firms rate CLLS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Underweight | $1.30 | Sep 16, 2026 |
| Citizens JMP | Mkt Perform | Sep 15, 2026 | |
| Jefferies | Buy | $7 | Feb 17, 2026 |
Questions about Robert W. Baird and CLLS
- What is Robert W. Baird's price target for CLLS?
- Robert W. Baird's latest stated price target for Cellectis S.A. (CLLS) is $10, from its action on May 18, 2022.
- What is Robert W. Baird's rating on CLLS?
- Robert W. Baird rates CLLS Outperform, a bullish rating, as of May 18, 2022.
- When did Robert W. Baird last change its view on CLLS?
- On May 18, 2022, Robert W. Baird upgrades to Outperform from Neutral, price target $10.
All Robert W. Baird ratingsCLLS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.